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QUESTIONS
1. Describe the role of NRAS and BRAF in melanoma development.
2. What is the hypothesis of the paper?
3. Describe the methods employed.
4. What were the findings of the study?
5. What may be the clinical implications of this study, and what future work could be performed?
Melanoma, the deadliest of skin cancers, is treatable if caught early, but prognosis 
worsens with disease progression. Therefore, a better understanding of the mecha-
nisms related to melanoma progression would be of great value. It is thought that 
melanoma is able to develop, grow, and subsequently spread because of genetic 
changes in cellular pathways. Mutations important in melanoma development have 
been found to occur in NRAS and BRAF, with recent studies reporting a BRAF muta-
tion rate of up to 80% in cutaneous melanomas (Davies et al., 2002; Goel et al., 2006). 
Smaller, but significant, percentages of melanomas have also been shown to have 
somatic mutations in NRAS (Smalley and Herlyn, 2005).
In contrast to invasive melanomas, in situ melanomas carry a lower frequency of NRAS and BRAF mutations 
(Dong et al., 2003); it is unclear whether advanced tumors have stable genotypes or acquire additional mutations 
as they progress (Omholt et al., 2003; Dong et al., 2003). In this issue, Greene and co-workers report an increase 
in the frequency of NRAS and BRAF mutations with the histologic transition from the radial (RGP) to the vertical 
growth phase (VGP).
Greene et al. used laser-capture microdissection to examine in situ melanomas as well as distinct areas of RGP 
and VGP of invasive melanomas. NRAS exon 2 and BRAF exon 15 DNA were amplified by PCR and sequenced. The 
authors found an increased frequency of mutations in invasive tumors; 75.9% exhibited VGP mutations and 55.2% 
exhibited RGP mutations. Both were more frequent than mutations found in in situ melanomas (40%). In some 
tumors, VGP mutations but no RGP mutations were detected; in tumors with both RGP and VGP mutations, VGP 
mutations were more frequent. These findings suggest that melanomas acquire additional genetic alterations 
with disease progression.
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to 
http://network.nature.com/group/jidclub.
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